| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $129,086 | 1 | 100 |
| Peters Jeffrey Stuart | Senior VP, GC, and Secretary | 0 | $0 | 1 | $129,086 | $-129,086 |
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; …
Over the last 12 months, insiders at MacroGenics, Inc. have bought $0 and sold $129,086 worth of MacroGenics, Inc. stock.
On average, over the past 5 years, insiders at MacroGenics, Inc. have bought $5.73M and sold $1.29M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 49,500 shares for transaction amount of $73,755 was made by HEIDEN WILLIAM K (director) on 2025‑08‑20.
| 2026-08-19 | Sale | Peters Jeffrey Stuart | Senior VP, GC, and Secretary | 31,105 0.0487% | $4.15 | $129,086 | -8.87% | |
| 2025-08-20 | HEIDEN WILLIAM K | director | 49,500 0.0783% | $1.49 | $73,755 | +29.53% | ||
| 2025-08-19 | HEIDEN WILLIAM K | director | 50,500 0.0815% | $1.52 | $76,760 | +28.86% | ||
| 2025-02-15 | Sale | Smith Beth Ann | VP, Controller & Treasurer | 423 0.0007% | $2.56 | $1,083 | -43.71% | |
| 2024-04-04 | Sale | Peters Jeffrey Stuart | Senior VP and General Counsel | 51,395 0.0725% | $15.55 | $799,148 | -80.20% | |
| 2024-03-06 | Sale | Peters Jeffrey Stuart | Senior VP and General Counsel | 19,625 0.0317% | $21.50 | $421,938 | -82.98% | |
| 2024-03-04 | Sale | Karrels James | SVP, CFO and Secretary | 30,000 0.0481% | $20.50 | $615,000 | -82.17% | |
| 2024-03-04 | Sale | Risser Eric Blasius | Chief Operating Officer | 41,159 0.0636% | $19.76 | $813,501 | -82.17% | |
| 2024-03-04 | Sale | Spitznagel Thomas | Sr VP, Technical Ops | 10,000 0.0156% | $20.00 | $200,000 | -82.17% | |
| 2024-02-26 | Sale | Peters Jeffrey Stuart | Senior VP and General Counsel | 16,124 0.0266% | $17.22 | $277,655 | -77.57% | |
| 2024-02-07 | Sale | Bonvini Ezio | Sr VP, Research & CSO | 3,334 0.0069% | $18.00 | $60,012 | -76.65% | |
| 2024-02-05 | Sale | Peters Jeffrey Stuart | Senior VP and General Counsel | 76,251 0.1454% | $16.50 | $1.26M | -75.52% | |
| 2024-02-01 | Sale | Bonvini Ezio | Sr VP, Research & CSO | 13,316 0.0231% | $15.00 | $199,740 | -73.02% | |
| 2024-01-19 | Sale | Bonvini Ezio | Sr VP, Research & CSO | 13,316 0.0216% | $12.00 | $159,792 | -64.71% | |
| 2023-12-20 | Sale | Bonvini Ezio | Sr VP, Research & CSO | 18,880 0.031% | $10.08 | $190,310 | -54.68% | |
| 2023-10-02 | BIOTECH TARGET N V | 10 percent owner | 150,000 0.2413% | $4.46 | $669,585 | +42.19% | ||
| 2023-09-07 | BIOTECH TARGET N V | 10 percent owner | 200,000 0.324% | $5.26 | $1.05M | +20.64% | ||
| 2023-08-30 | HURWITZ EDWARD | director | 15,000 0.0244% | $4.91 | $73,650 | +30.00% | ||
| 2023-03-10 | Sale | Peters Jeffrey Stuart | Senior VP and General Counsel | 5,372 0.0099% | $6.03 | $32,393 | +19.64% | |
| 2023-02-14 | BIOTECH TARGET N V | 10 percent owner | 500,000 0.7819% | $5.07 | $2.53M | +15.84% |
| BIOTECH TARGET N V | 10 percent owner | 9929963 15.5886% | $23.14M | 19 | 0 | <0.0001% |
| Karrels James | SVP, CFO and Secretary | 171452 0.2692% | $399,483.16 | 1 | 3 | +137.87% |
| HEIDEN WILLIAM K | director | 111000 0.1743% | $258,630.00 | 2 | 0 | +29.19% |
| Costa Paulo F | director | 59435 0.0933% | $138,483.55 | 1 | 0 | +41.83% |
| HURWITZ EDWARD | director | 33074 0.0519% | $77,062.42 | 1 | 1 | |
| Galbraith Kenneth | director | 0 0% | $0 | 1 | 1 | <0.0001% |
$16,280,851 | 76 | 1.48% | $118.27M | |
$6,788,859 | 35 | 26.72% | $151.54M | |
$7,147,964 | 34 | 24.77% | $166.39M | |
$47,438,336 | 33 | -21.38% | $122.37M | |
$38,621,826 | 31 | 1.43% | $157.74M |
| Increased Positions | 42 | +32.81% | 11M | +24.7% |
| Decreased Positions | 53 | -41.41% | 18M | -38.26% |
| New Positions | 13 | New | 4M | New |
| Sold Out Positions | 24 | Sold Out | 14M | Sold Out |
| Total Postitions | 117 | -8.59% | 40M | -13.56% |
| Bellevue Group Ag | $15,971.00 | 15.75% | 9.92M | 0 | 0% | 2025-09-30 |
| Armistice Capital, Llc | $9,596.00 | 9.46% | 5.96M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $6,801.00 | 6.71% | 4.22M | +11,120 | +0.26% | 2025-09-30 |
| Frazier Life Sciences Management, L.P. | $5,113.00 | 5.04% | 3.18M | 0 | 0% | 2025-09-30 |
| Acadian Asset Management Llc | $4,053.00 | 4% | 2.52M | +25,844 | +1.04% | 2025-09-30 |
| Millennium Management Llc | $3,408.00 | 3.36% | 2.12M | +101,006 | +5.01% | 2025-09-30 |
| Wasatch Advisors Lp | $3,140.00 | 3.1% | 1.95M | -1M | -40.01% | 2025-09-30 |
| Renaissance Technologies Llc | $2,739.00 | 2.7% | 1.7M | +374,729 | +28.25% | 2025-09-30 |
| Blackrock, Inc. | $2,477.00 | 2.44% | 1.54M | -278,835 | -15.34% | 2025-09-30 |
| Morgan Stanley | $1,593.00 | 1.57% | 989,233 | +543,011 | +121.69% | 2025-09-30 |